QG101-23-0 not checked
Amckaus PTY LTD. · Aom0304
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The first dose of Aom0304 is to be administered orally under supervision, the second dose it to be administered orally at home. Participants will be supplied with Aom0304 for BID dosing orally at home. During the treatment period of 12 weeks, participants will receive the assigned dosing according to cohort allocation and dose titration strategy. There will be a Dose titration phase and…”In the company’s words, NCT07675668 on ClinicalTrials.gov
- Tested for
- Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM), Non-obstructive HCM (nHCM)
- Main trialPhase 2
- “The goal of this clinical trial is designed to characterise the safety, tolerability, efficacy, and PK of Aom0304 across oHCM and nHCM populations and to inform dose selection for future Phase 3 development. The main questions it aims to answer are: 1. Which dose is safe and tolerant of Aom0304 in participants with HCM? 2. Which dose is effective of 12 weeks of Aom0304 treatment in participants with oHCM or nHCM? Researchers will compare different doses of Aom0304 to see which works best. All participants will receive Aom0304, but at different dose levels depending on which cohort they…”In the company’s words, NCT07675668 on ClinicalTrials.gov
- Other names
- Aom0304
Other drugs for Hypertrophic Cardiomyopathy (HCM)
- SotagliflozinLexicon Pharmaceuticals · Phase 3
- HRS-1893Hengrui · Phase 3
- BHB-1893Braveheart Bio, Inc. · Phase 3
- AficamtenCytokinetics · Phase 2/3
- BAY3723113Bayer · Phase 3
- NinerafaxstatImbria Pharmaceuticals, Inc. · Phase 2
Coming up1
- 30 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Dec 2027 | Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy | |
| Phase 1Completed | 24 Jan 2024 | QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026